{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:58:51Z","timestamp":1792792731370,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jaip.2023.11.007","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:34:33Z","timestamp":1699990473000},"page":"409-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and Safety of Biologics for Oral Corticosteroid\u2013Dependent Asthma: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Phichayut","family":"Phinyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanachit","family":"Krikeerati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irin","family":"Vichara-Anont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torpong","family":"Thongngarm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.11.007_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.11.007_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.007_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Frossing","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.007_bib5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.11.007_bib7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib9","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.11.007_bib10","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.11.007_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13730","article-title":"Rational oral corticosteroid use in adult severe asthma: a narrative review","volume":"25","author":"Chung","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2023.11.007_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MCP.0000000000000541","article-title":"Oral corticosteroid-dependent asthma: current knowledge and future needs","volume":"25","author":"Pavord","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2019","article-title":"Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study","volume":"54","author":"Lee","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.11.007_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/thoraxjnl-2018-212709","article-title":"Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study","volume":"74","author":"Busby","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2023.11.007_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/thoraxjnl-2018-211657","article-title":"Change in biomarkers of type-2 inflammation following severe exacerbations of asthma","volume":"74","author":"Semprini","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2023.11.007_bib18","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.jaip.2023.11.007_bib19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2023.11.007_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"van de Schoot","year":"2021","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.jaip.2023.11.007_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jaip.2023.11.007_bib22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2023.11.007_bib23","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2023.11.007_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2023.11.007_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2023.11.007_bib27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00948-2018","article-title":"Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma","volume":"53","author":"Busse","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.11.007_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib31","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib32","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with\u00a0oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib37","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/rccm.202003-0729LE","article-title":"Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma","volume":"202","author":"Moran","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib40","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.11.007_bib41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaip.2023.11.007_bib43","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1513\/AnnalsATS.201901-071OC","article-title":"Placebo effects in clinical trials evaluating patients with uncontrolled persistent asthma","volume":"16","author":"Luc","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2023.11.007_bib44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2468-1253(21)00470-2","article-title":"Ranking treatments in the network meta-analysis should consider the certainty of evidence","volume":"7","author":"Li","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823012497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823012497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:40:25Z","timestamp":1761975625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823012497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2213219823012497"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.11.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Biologics for Oral Corticosteroid\u2013Dependent Asthma: A Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}